17 results on '"Janssen NM"'
Search Results
2. Initiation of disease-modifying antirheumatic drug therapy in minority and disadvantaged patients with rheumatoid arthritis.
- Author
-
Suarez-Almazor ME, Berrios-Rivera JP, Cox V, Janssen NM, Marcus DM, and Sessoms S
- Published
- 2007
3. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation.
- Author
-
Janssen NM and Genta MS
- Published
- 2000
- Full Text
- View/download PDF
4. Successful treatment of a persistent air leak with an endobronchial valve in a 17-year-old patient with necrotizing pneumonia.
- Author
-
Janssen NM, Posthuma R, Kienhorst S, Bannier MAGE, Lalji UC, Franssen FME, and Sprooten RTM
- Abstract
Pleural empyema is a severe condition associated with high morbidity and mortality. Treatment usually consists of pleural drainage with chest tube or surgery, in combination with antimicrobial treatment. Severe pneumonia can evolve in a necrotizing pneumonia, given a higher susceptibility to the occurrence of bronchopleural fistulas with persistent air leaks. This complicates recovery, and surgery may not always be the optimal treatment. We present a case involving a 17-year-old female patient who experienced a post-operative persistent air leak due to necrotizing pneumonia after video-assisted thoracic surgery decortication for empyema, which was successfully treated using an endobronchial valve. After 6 months the valve was removed without complications. Follow-up imaging and lung function revealed a limited area of atelectasis and minimal pleural thickening with normal lung volumes., Competing Interests: None declared., (© 2024 The Author(s). Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.)
- Published
- 2024
- Full Text
- View/download PDF
5. Adaptive automation: automatically (dis)engaging automation during visually distracted driving.
- Author
-
Cabrall CDD, Janssen NM, and de Winter JCF
- Abstract
Background: Automated driving is often proposed as a solution to human errors. However, fully automated driving has not yet reached the point where it can be implemented in real traffic. This study focused on adaptively allocating steering control either to the driver or to an automated pilot based on momentary driver distraction measured from an eye tracker., Methods: Participants ( N = 31) steered a simulated vehicle with a fixed speed, and at specific moments were required to perform a visual secondary task (i.e., changing a CD). Three conditions were tested: (1) Manual driving (Manual), in which participants steered themselves. (2) An automated backup (Backup) condition, consisting of manual steering except during periods of visual distraction, where the driver was backed up by automated steering. (3) A forced manual drive (Forced) condition, consisting of automated steering except during periods of visual distraction, where the driver was forced into manual steering. In all three conditions, the speed of the vehicle was automatically kept at 70 km/h throughout the drive., Results: The Backup condition showed a decrease in mean and maximum absolute lateral error compared to the Manual condition. The Backup condition also showed the lowest self-reported workload ratings and yielded a higher acceptance rating than the Forced condition. The Forced condition showed a higher maximum absolute lateral error than the Backup condition., Discussion: In conclusion, the Backup condition was well accepted, and significantly improved performance when compared to the Manual and Forced conditions. Future research could use a higher level of simulator fidelity and a higher-quality eye-tracker., Competing Interests: The authors declare there are no competing interests., (©2018 Cabrall et al.)
- Published
- 2018
- Full Text
- View/download PDF
6. Uterine artery pseudoaneurysm requiring embolization during pregnancy.
- Author
-
Cornette J, van der Wilk E, Janssen NM, van der Weiden RMF, Jenninkens SFM, Pattynama P, and Duvekot JJ
- Subjects
- Adult, Female, Humans, Pregnancy, Aneurysm, False therapy, Pregnancy Complications, Cardiovascular therapy, Uterine Artery, Uterine Artery Embolization
- Abstract
Background: Uterine artery pseudoaneurysm has a pathognomonic ultrasound appearance. Its occurrence in pregnancy is life-threatening for both mother and fetus. We present an illustrative case and discuss management with selective uterine artery embolization during pregnancy., Case: A 37-year-old pregnant woman presented with profuse painless vaginal blood loss at a gestational age of 27 weeks. Ultrasonography and magnetic resonance imaging indicated a left-sided uterine artery pseudoaneurysm. Selective embolization of the pseudoaneurysm was performed. Blood loss ceased allowing the pregnancy to continue until term., Conclusion: Endovascular embolization is a feasible therapeutic option for a uterine artery pseudoaneurysm during pregnancy without compromising fetoplacental perfusion.
- Published
- 2014
- Full Text
- View/download PDF
7. Patient satisfaction with intranasal fentanyl for breakthrough pain.
- Author
-
Veldhorst-Janssen NM, Fiddelers AA, Zandstra H, Kessels AG, Zandstra H, Marcus MA, Neef C, and van der Kuy PH
- Subjects
- Adolescent, Adult, Aged, Analgesics, Opioid therapeutic use, Female, Fentanyl therapeutic use, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Surveys and Questionnaires, Young Adult, Administration, Intranasal, Analgesics, Opioid administration & dosage, Breakthrough Pain drug therapy, Fentanyl administration & dosage, Patient Satisfaction
- Published
- 2012
- Full Text
- View/download PDF
8. Management of pituitary tumour apoplexy with bromocriptine in pregnancy.
- Author
-
Janssen NM, Dreyer K, and van der Weiden RM
- Published
- 2012
- Full Text
- View/download PDF
9. Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study.
- Author
-
Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH, Theunissen HM, de Krom MC, Neef C, and Marcus MA
- Subjects
- Administration, Intranasal, Adult, Anticonvulsants adverse effects, Cross-Over Studies, Female, Humans, Infusions, Intravenous, Male, Midazolam adverse effects, Middle Aged, Nasal Sprays, Netherlands, Pilot Projects, Anticonvulsants administration & dosage, Anticonvulsants pharmacokinetics, Midazolam administration & dosage, Midazolam pharmacokinetics
- Abstract
Background: Intranasal (IN) midazolam is a potential alternative to rectal diazepam for the acute treatment of epileptic seizures., Objective: The purpose of this pilot study was to investigate the pharmacokinetics and tolerability of IN midazolam (50 mg/mL) compared with intravenous (IV) midazolam (2.5 mg) in healthy adult volunteers., Methods: In this single-dose, randomized-sequence, open-label, 2-period crossover pilot study subjects were randomly assigned to receive IN or IV midazolam, with a washout period of at least 5 days between treatments. The 50-mg/mL IN midazolam formulation consisted of 5 mg midazolam base per 0.1 mL (1 spray) and was administered once in 1 nostril. The IV midazolam solution (2.5 mg) was infused over 10 seconds. Blood samples were taken before and at regular intervals up to 240 minutes after dosing. Pharmacokinetic data (ie, C(max), T(max), t(½), and AUC) were analyzed using a 2-compartment model., Results: Of 9 volunteers screened and enrolled, 7 completed the study (mean age 34.1 [9.0] years; mean weight, 68.6 [10.4] kg, range 53-89 kg; 6 men, 3 women; all white). The mean C(max) of 78 (40) ng/mL was reached 44 minutes after IN administration, whereas the mean C(max) was 51 (5) ng/mL after IV administration. The mean estimated C(t=5 min) was 31.4 (28.1) ng/mL after IN administration. The elimination t(½) was 1.9 (0.41) hours for IN midazolam and 2.3 (0.19) hours for IV midazolam. The bioavailability of IN midazolam was 82%. There were few adverse events, with a local burning feeling in the nose being the most reported event (6 of 7 subjects)., Conclusions: In this select group of healthy volunteers, concentrations of midazolam >30 ng/mL were reached within 5 minutes of IN administration at a dose of 5 mg/0.1 mL. A burning feeling in the nostril was the main adverse effect. Additional research is needed to evaluate the safety profile, convenience, satisfaction, and efficacy of nasal midazolam in the treatment of adults with seizures. This trial is registered at www.isrctn.org, No. ISRCTN79059168., (Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
10. Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study.
- Author
-
Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH, Kessels AG, Theunissen HM, van der Hulst RR, Neef C, and Marcus MA
- Subjects
- Administration, Intranasal, Adolescent, Adult, Analgesics, Opioid administration & dosage, Analgesics, Opioid adverse effects, Device Removal methods, Double-Blind Method, Drainage, Female, Fentanyl administration & dosage, Fentanyl adverse effects, Humans, Middle Aged, Pain etiology, Pain Measurement, Prospective Studies, Time Factors, Young Adult, Analgesics, Opioid therapeutic use, Fentanyl therapeutic use, Mammaplasty methods, Pain drug therapy
- Abstract
Background: Although acetaminophen is used to reduce pain after breast reduction or augmentation surgery, pain during the removal of the surgical drains is typically not specifically treated. Intranasally administered fentanyl may be suitable for pain control during removal of drains. The reported therapeutic window of fentanyl is between 0.2 and 1.2 ng/mL., Objective: The aim of this study was to evaluate the analgesic effect, tolerability, and pharmacokinetics of a single preprocedural dose of intranasal fentanyl administered before removal of surgical drains in patients who had undergone breast reduction or augmentation surgery., Methods: This was a randomized, double-blind, prospective study in healthy women (American Society of Anesthesiologists physical status I or II) between the ages of 18 and 65 years who were scheduled to undergo removal of surgical drains 1 to 4 days after breast reduction or augmentation surgery. A single dose of fentanyl nasal spray 0.05 mg/0.1 mL or placebo (preserved normal saline) 0.1 mL was administered 10 minutes before removal of drains. Because drain removal is generally carried out without specific analgesia, no rescue medication was provided. Pain intensity was measured on a visual analog scale (VAS) from 0 = no pain at all to 100 = worst pain possible. Pain intensity was evaluated immediately before administration of study medication (t = 0), at the time of drain removal (t = 10), and at 15, 20, 25, 40, and 70 minutes after administration of study medication. Safety measures included oxygen saturation, respiratory rate, heart rate, and blood pressure. Local and systemic adverse events were elicited by direct questioning throughout the study. Blood samples for pharmacokinetic analysis were collected at baseline and at 5, 10, 15, 30, 60, and 120 minutes after administration of study medication. The population pharmacokinetic parameters of fentanyl were calculated according to a 1-compartment open model with an iterative 2-stage Bayesian fitting procedure., Results: Thirty-six women were randomized to treatment, and 33 completed the study. Their mean (SD) age was 39.2 (13.0) years, and their mean weight was 68.9 (10.7) kg. Mean VAS scores at baseline were 14.8 (17.8) for the fentanyl group and 6.0 (9.7) for the placebo group (P = NS); at the time of drain removal, the corresponding VAS scores were 31.0 (20.6) and 33.8 (25.7) (P = NS). Analysis of a random-effects model with mean VAS scores as a function of time as the dependent variable indicated a significant difference in mean VAS scores between the fentanyl and placebo groups (P = 0.006). The overall incidence of adverse events was 39.4% (13/33). Among the 17 patients in the fentanyl group, 8 reported > or =1 adverse event; among the 16 patients in the placebo group, 9 reported > or =1 adverse event. A mean estimated C(max) of 0.184 (0.069) ng/mL was reached at 13.76 (3.56) minutes after administration of intranasal fentanyl. The mean measured C(max) was 0.22 (0.088) ng/mL., Conclusions: In these women who had undergone breast reduction or augmentation surgery, a single preprocedural dose of intranasal fentanyl was significantly more effective than placebo in reducing pain intensity over the hour after removal of surgical drains. However, there was no significant difference in pain intensity between fentanyl at the time of drain removal and placebo. Intranasal fentanyl was generally well tolerated. At the dose used (0.05 mg), plasma fentanyl concentrations were below the reported therapeutic window., (2010 Excerpta Medica Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
11. A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally.
- Author
-
Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH, Neef C, and Marcus MA
- Subjects
- Administration, Intranasal, Administration, Oral, Aerosols, Benzodiazepines administration & dosage, Benzodiazepines adverse effects, Biological Availability, Female, Humans, Injections, Intravenous, Male, Narcotic Antagonists administration & dosage, Narcotic Antagonists adverse effects, Benzodiazepines pharmacokinetics, Migraine Disorders drug therapy, Narcotic Antagonists pharmacokinetics
- Abstract
Background: Interest in the development of drug-delivery devices that might improve treatment compliance is growing. A dosage formulation that is easy to use, such as intranasal application with transmucosal absorption, may offer advantages compared with other routes of drug delivery. The literature concerning intranasal application is diffuse, with a large number of published studies on this topic. Some cerebroactive pharmaceuticals delivered intranasally might follow the pathway from the nose to the systemic circulation to the brain. To determine the suitability of these drugs for intranasal drug delivery, a systematic review was performed., Objective: The aim of this review was to compare the pharmacokinetic properties of intranasal, intravenous, and oral formulations in 3 classes of cerebroactive drugs that might be suitable for intranasal delivery-opioids, benzodiazepines, and antimigraine agents., Methods: A search of MEDLINE, PubMed, Cumulative Index of Nursing and Allied Health Literature, EMBASE, and Cochrane Database of Systematic Reviews (dates: 1964-April 2009) was conducted for pharmacokinetic studies of drugs that might be suitable for intranasal delivery. A comparison of pharmacokinetic data was made between these 3 routes of administration., Results: A total of 45 studies were included in this review. Most of the opioids formulated as an intranasal spray reached a T(max) within 25 minutes. The bioavailability of intranasal opioids was high; in general, >50% compared with opioids administered intravenously. Intranasal benzodiazepines had an overall T(max) that varied from 10 to 25 minutes, and bioavailability was between 38% and 98%. T(max) for most intranasal antimigraine drugs varied from 25 to 90 minutes. Intranasal bioavailability varied from 5% to 40%., Conclusions: This review found that intranasal administration of all 3 classes of drugs was suitable for indications of rapid delivery, and that the pharmacokinetic properties differed between the intranasal, oral, and intravenous formulations (intravenous > intranasal > oral)., (Copyright 2009 Excerpta Medica Inc. All rights reserved.)
- Published
- 2009
- Full Text
- View/download PDF
12. Factors influencing bar-code verification by nurses during medication administration in a Dutch hospital.
- Author
-
van Onzenoort HA, van de Plas A, Kessels AG, Veldhorst-Janssen NM, van der Kuy PH, and Neef C
- Subjects
- Adult, Age Factors, Attitude of Health Personnel, Attitude to Computers, Drug Labeling, Hospitals, University, Humans, Medication Errors prevention & control, Middle Aged, Netherlands, Organizational Case Studies, Patient Identification Systems, Point-of-Care Systems, Safety Management methods, Time Factors, Diffusion of Innovation, Electronic Data Processing, Guideline Adherence, Medication Systems, Hospital organization & administration, Nursing Staff, Hospital supply & distribution, Total Quality Management methods
- Abstract
Purpose: Factors influencing the bar-code verification by nurses during medication administration in a Dutch hospital were studied., Summary: The use of bar-code verification during medication administration in five medical departments was recorded daily for three weeks. These data were collected via electronic medication administration records. The frequency of bar-code verification was calculated as a percentage of all administrations, corrected for the availability of bar-coded packages. Nurses were asked why bar-code verification was not always used. A total of 23,492 medication administrations were recorded, 15,162 (64.5%) of which required bar-code verification. Bar-code verification was significantly influenced by the medical department, deviation between prescribed and administered times, administration route of the drug, number of nurses available in each department, and age of the nurse. The five most cited reasons for not verifying bar codes were difficulties in scanning bar codes on the medication labels, lack of awareness of bar codes on medication labels, delays in responses from the computerized system, shortage of time, and administration of medication before prescription., Conclusion: Nurses verified the bar codes of only about half of medications administered to patients. Various factors influenced the frequency of bar-code verification by nurses except the number of medications administered. More education regarding medication safety is warranted to increase compliance to a bar-code-enabled point-of-care system.
- Published
- 2008
- Full Text
- View/download PDF
13. Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosus.
- Author
-
Berrios-Rivera JP, Street RL Jr, Garcia Popa-Lisseanu MG, Kallen MA, Richardson MN, Janssen NM, Marcus DM, Reveille JD, Warner NB, and Suarez-Almazor ME
- Subjects
- Adult, Black or African American ethnology, Arthritis, Rheumatoid ethnology, Communication, Cross-Sectional Studies, Decision Making, Female, Hispanic or Latino ethnology, Humans, Lupus Erythematosus, Systemic ethnology, Male, Middle Aged, Patient Satisfaction ethnology, Surveys and Questionnaires, Texas, Truth Disclosure, White People ethnology, Arthritis, Rheumatoid psychology, Lupus Erythematosus, Systemic psychology, Physician-Patient Relations, Physicians psychology, Trust psychology
- Abstract
Objective: To identify components of the patient-doctor relationship associated with trust in physicians., Methods: We assessed 102 patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) seen at publicly funded hospitals in Houston, Texas. Patients completed a self-response survey examining patient perceptions of the medical encounter and trust in their physicians. Evaluated components of physicians' behaviors included: informativeness, sensitivity to concerns, reassurance and support, patient-centeredness, and participatory decision-making style. Scales were scored 0 to 10, with higher numbers indicating more positive perceptions of communication., Results: Seventy patients had RA and 32 SLE; 25% were white, 43% Latino, 31% African American, and 75% were female. Mean scores for the medical interaction and trust scales ranged from 6.2-7.1, indicating moderate degrees of positive perceptions. All components were highly and positively correlated with each other, and with trust, suggesting that these traits are all elements of a positive style of doctor-patient communication. In multivariate analysis, ethnicity, physicians' informativeness, physicians' sensitivity to concerns, patient-centeredness, disease activity, and patient trust in the US health care system were independent predictors of trust in physicians. A separate model examined the predictors of patient disclosure of information. Patient perceptions of physicians' patient-centeredness and severity of disease activity were independently predictive of patient disclosure of information., Conclusion: In patients with SLE and RA, trust in physicians is significantly associated with patients' ethnicity and their perceptions about specific components of physicians' communication style. Trust in physicians can be improved by using a patient-centered approach, being sensitive to patient concerns, and providing adequate clinical information. Furthermore, patients appear to be more willing to disclose concerns when physicians use a patient-centered communication style.
- Published
- 2006
- Full Text
- View/download PDF
14. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease.
- Author
-
Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, O'Malley KJ, Janssen NM, Marcus DM, Tagore J, and Suarez-Almazor ME
- Subjects
- Adult, Antirheumatic Agents economics, Appointments and Schedules, Arthritis, Rheumatoid economics, Arthritis, Rheumatoid ethnology, Communication Barriers, Cultural Diversity, Drug Costs, Female, Focus Groups, Humans, Language, Lupus Erythematosus, Systemic economics, Lupus Erythematosus, Systemic ethnology, Male, Middle Aged, Patient Satisfaction statistics & numerical data, Poverty statistics & numerical data, Severity of Illness Index, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Lupus Erythematosus, Systemic drug therapy, Patient Compliance statistics & numerical data, Vulnerable Populations statistics & numerical data
- Abstract
Objective: To explore the determinants of adherence to medical recommendations, including drug therapy and appointment-keeping, among ethnically diverse and economically disadvantaged patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)., Methods: Patients with RA and SLE were identified through chart review and were invited to participate in focus groups to examine their attitudes and beliefs regarding adherence to treatment and medical appointments. Eight focus groups (4 RA, 4 SLE) were conducted, with a total of 40 participants (22 SLE patients and 18 RA patients). Transcripts were analyzed using grounded theory techniques and qualitative analysis software to facilitate coding interpretation., Results: The majority of participants reported experiencing difficulty in adhering to their treatment at least occasionally. Both SLE and RA patients reported similar barriers to treatment adherence: fear of side effects, financial problems, difficulty in navigating the public health system, and perceived treatment inefficacy. RA and SLE patients also revealed barriers to appointment keeping, including difficulties in scheduling, financial costs, transportation, and functional impairment limiting their ability to attend the clinic., Conclusion: Patients' perceptions of and experiences with the health system, physicians, medication effectiveness, and side effects influence their adherence to treatment and other medical recommendations. Strategies to improve adherence could include the following: attempting to modify patients' beliefs and perceptions regarding medication effectiveness, promoting realistic expectations about risk/benefit ratios, and improving access to health care by reducing barriers that limit the interaction between patients and the health system.
- Published
- 2005
15. Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.
- Author
-
Veldhorst-Janssen NM, Boersma HH, de Krom MC, and van Rijswijk RE
- Subjects
- Administration, Oral, Anticonvulsants therapeutic use, Antimetabolites, Antineoplastic therapeutic use, Carcinoma drug therapy, Drug Interactions, Epilepsy drug therapy, Humans, Leucovorin therapeutic use, Male, Middle Aged, Phenytoin therapeutic use, Rectal Neoplasms drug therapy, Tegafur therapeutic use, Anticonvulsants adverse effects, Antimetabolites, Antineoplastic pharmacology, Leucovorin pharmacology, Phenytoin adverse effects, Tegafur pharmacology
- Published
- 2004
- Full Text
- View/download PDF
16. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome.
- Author
-
Janssen NM, Karnad DR, and Guntupalli KK
- Subjects
- Humans, Infections complications, Intensive Care Units statistics & numerical data, Prognosis, Rheumatic Diseases complications, Rheumatic Diseases diagnosis, Critical Care methods, Rheumatic Diseases epidemiology, Rheumatic Diseases therapy
- Abstract
Patients with systemic rheumatic diseases may be admitted to the ICU because of worsening of or development of a new manifestation of the rheumatic disease, infections caused by immunosuppression, or adverse effects of drugs used to treat rheumatic diseases. Sometimes an unrelated, acute disorder may become life threatening because of the underlying rheumatic disorder. Rheumatoid arthritis is the most common rheumatic disease seen in ICU patients, followed by systemic lupus erythematosus and scleroderma. These three conditions together account for up to 75% of rheumatic cases admitted to the ICU. The respiratory system is the organ system most commonly affected in the acute process, followed by the renal, gastrointestinal, and nervous systems. More than 50% of admissions result from infections, and 25% to 35% result from exacerbation of the underlying rheumatic condition. In about 20% of patients, the rheumatic disorder may be diagnosed for the first time in the ICU. An aggressive approach should be pursued to establish the diagnosis of either disease exacerbation or infection. Delay in instituting appropriate immunosuppressive or antimicrobial therapy may result in multiple organ system failure and a poor outcome. The mortality rate in patients with rheumatic disease exceeds that predicted by the APACHE II or SAPS II scores and is higher than that in nonrheumatologic ICU admissions. The mortality may exceed 50% in patients admitted for infection; the prognosis is comparatively better for patients with exacerbations of disease activity. Renal failure, coma, and acute abdomen are predictors of poor outcome. Early recognition of abdominal complications requiring surgical intervention may help reduce mortality.
- Published
- 2002
- Full Text
- View/download PDF
17. Subcutaneous nodular amyloidosis: a case report and review of the literature.
- Author
-
Nguyen TU, Oghalai JS, McGregor DK, Janssen NM, and Huston DP
- Subjects
- Adult, Amyloid analysis, Amyloidosis metabolism, Amyloidosis pathology, Antibodies, Monoclonal, Bence Jones Protein urine, Biopsy, Female, Humans, Immunoglobulin M blood, Immunoglobulin lambda-Chains blood, Immunohistochemistry, Male, Middle Aged, Muscle, Skeletal pathology, Proteinuria urine, Tomography, X-Ray Computed, Amyloidosis diagnosis, Neck
- Abstract
Amyloidosis typically manifests with disseminated infiltration of multiple organ systems. Rarely, amyloidosis may be localized. We report a patient with localized subcutaneous nodular amyloidosis, without systemic amyloid involvement or myeloma, whose presenting symptom was multiple discrete neck nodules. Immunohistochemical analysis showed the amyloid deposits to be derived from lambda light chains. Twenty-four month follow-up showed minimal disease progression. A literature review showed only 5 reported cases of subcutaneous nodular amyloidosis. This is the first description of a patient with subcutaneous nodular amyloidosis derived from lambda light chains. HUM PATHOL 32:346-348., (Copyright 2001 by W.B. Saunders Company)
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.